Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Anxiety wasn’t associated with increased risk, but persistent depression may be a warning flag for people with metastatic lung cancer.
Exkivity is approved for adults with advanced non-small-cell lung cancer with specific EGFR mutations.
Patricia Hom, MD, MPH, 39, who trained as an ob-gyn, lives in San Francisco. She has Stage IV metastatic non-small-cell lung cancer.
Lumakras (sotorasib) was granted accelerated approval for the treatment of advanced non-small-cell lung cancer.
National Cancer Institute study describes three molecular subtypes of lung cancer in people who have never smoked.
Current and former smokers had better clinical outcomes with checkpoint inhibitors for lung cancer than nonsmokers.
But individuals who sought surgery soon after diagnosis had better outcomes.
Tecentriq after surgery and chemotherapy delayed recurrence in people with Stage II or III non-small-cell lung cancer.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
Rybrevant is the first treatment for people with advanced non-small-cell lung cancer whose tumors have EGFR exon 20 insertion mutations.
The response rate was nearly 50% for people with breast, colon, pancreatic and other cancers.
More than 80% of lung cancer patients treated with the targeted therapy experienced remission or had stable disease.
Here are latest cancer drugs approved by the Food and Drug Administration.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.